Skip to main content

09-20-2017 | Type 1 diabetes | Video

Expert commentary: DEPICT-1 and inTandem3

Parth Narendran discusses the findings of two trials testing SGLT2 inhibitors in patients with type 1 diabetes (5:47).
Read the accompanying news stories on the DEPICT-1 and inTandem3 results

More on this topic

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »